Neos Therapeutics Stock Soars on 3rd Unsolicited Buyout Offer From PDL BioPharma

6y ago, source: TheStreet.com

Pharmaceutical company Neos received an offer for $10.25 per share, which would value the deal around $288 million. It's the third time PDL has tried to make a deal. Pharmaceutical company Neos ...

Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With ...

1mon ago, source: ADVFN

Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that leading independent ...

Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on Marc...

1mon ago, source: ADVFN

Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, and Neos Therapeutics, Inc. (NASDAQ ...

Seelos Therapeutics Inc SEEL

4d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

ELVN Enliven Therapeutics, Inc.

3d ago, source: Seeking Alpha

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead ...

NEOS-223 shows potent antitumoral activity both in vitro and in vivo

8d ago, source: BioWorld

Kinase inhibitors have emerged as crucial cancer therapeutics due to the involvement of kinases in cancer signaling. At the AACR, Neosome Life Sciences LLC has provided data on their kinase inhibitor ...

MCRB Seres Therapeutics, Inc.

1d ago, source: Seeking Alpha

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that ...

Cyclo Therapeutics Inc CYTH

12h ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Fate Therapeutics, Inc.

9d ago, source: CNN

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno ...

Q4 2023 Design Therapeutics Inc Earnings Call

27d ago, source: Yahoo Finance

Sean Jeffries; COO; Design Therapeutics, Inc. Pratik Shah; Co-Founder, President, and Chairperson; Design Therapeutics, Inc. Operator And welcome to design's conference call at this time.

Coya Therapeutics, Inc. (COYA) Interactive Stock Chart - Yahoo Finance

20h ago, source: Yahoo Finance

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Coya Therapeutics... HOUSTON, March 19, 2024--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or ...

Intellia Therapeutics, Inc.

3mon ago, source: CNN

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms ...